| Thomas Nicholson, MD | |
|
1125 Route 22 Ste 170, Bridgewater, NJ 08807-2939 | |
| (908) 647-7022 | |
| (908) 947-7011 |
| Full Name | Thomas Nicholson |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 10 Years |
| Location | 1125 Route 22 Ste 170, Bridgewater, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083032668 | NPI | - | NPPES |
| 0400988 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | 25MA11720900 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Morristown Medical Center | Morristown, NJ | Hospital |
| Overlook Medical Center | Summit, NJ | Hospital |
| Ohiohealth Mansfield Hospital | Mansfield, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Practice Associates Medical Group | 5890703177 | 1116 |
News Archive
Pediatric and Developmental Pathology - Gonadal dysgenesis—defective development of the ovaries or testes— may also bring with it an increased risk of gonadal tumors. A recent discovery at the histologic level could help identify cells at risk of conversion into a tumor.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that generic erosion of several established branded atypical antipsychotics will cause the schizophrenia drug market to decrease from $6.3 billion in 2008 to $5.2 billion in 2013 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
Although Justice Alito said the Hobby Lobby decision would affect only a narrow group, others say many firms could fit in the definition of 'closely held.'
News media registration opened today for the American Chemical Society's (ACS') 243rd National Meeting & Exposition, one of the largest scientific conferences of the New Year.
On January 26, 2010, the Food and Drug Administration (FDA) released a key draft guidance document, Guidance for Industry Assessment of Abuse Potential of Drugs. When finalized, this guidance will represent the FDA's current position on the abuse potential of drugs. Noteworthy within the document, Good Laboratory Practices (GLP) specified in the Guidance for Industry S7A Safety 471 Pharmacology Studies for Human Pharmaceuticals and in FDA regulations, 21 CFR 472 part 58, now also apply to abuse potential studies in animals.
› Verified 9 days ago
| Entity Name | Practice Associates Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427016385 PECOS PAC ID: 5890703177 Enrollment ID: O20060330000690 |
News Archive
Pediatric and Developmental Pathology - Gonadal dysgenesis—defective development of the ovaries or testes— may also bring with it an increased risk of gonadal tumors. A recent discovery at the histologic level could help identify cells at risk of conversion into a tumor.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that generic erosion of several established branded atypical antipsychotics will cause the schizophrenia drug market to decrease from $6.3 billion in 2008 to $5.2 billion in 2013 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
Although Justice Alito said the Hobby Lobby decision would affect only a narrow group, others say many firms could fit in the definition of 'closely held.'
News media registration opened today for the American Chemical Society's (ACS') 243rd National Meeting & Exposition, one of the largest scientific conferences of the New Year.
On January 26, 2010, the Food and Drug Administration (FDA) released a key draft guidance document, Guidance for Industry Assessment of Abuse Potential of Drugs. When finalized, this guidance will represent the FDA's current position on the abuse potential of drugs. Noteworthy within the document, Good Laboratory Practices (GLP) specified in the Guidance for Industry S7A Safety 471 Pharmacology Studies for Human Pharmaceuticals and in FDA regulations, 21 CFR 472 part 58, now also apply to abuse potential studies in animals.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Thomas Nicholson, MD Po Box 416457, Boston, MA 02241-6457 Ph: (844) 362-1735 | Thomas Nicholson, MD 1125 Route 22 Ste 170, Bridgewater, NJ 08807-2939 Ph: (908) 647-7022 |
News Archive
Pediatric and Developmental Pathology - Gonadal dysgenesis—defective development of the ovaries or testes— may also bring with it an increased risk of gonadal tumors. A recent discovery at the histologic level could help identify cells at risk of conversion into a tumor.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that generic erosion of several established branded atypical antipsychotics will cause the schizophrenia drug market to decrease from $6.3 billion in 2008 to $5.2 billion in 2013 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
Although Justice Alito said the Hobby Lobby decision would affect only a narrow group, others say many firms could fit in the definition of 'closely held.'
News media registration opened today for the American Chemical Society's (ACS') 243rd National Meeting & Exposition, one of the largest scientific conferences of the New Year.
On January 26, 2010, the Food and Drug Administration (FDA) released a key draft guidance document, Guidance for Industry Assessment of Abuse Potential of Drugs. When finalized, this guidance will represent the FDA's current position on the abuse potential of drugs. Noteworthy within the document, Good Laboratory Practices (GLP) specified in the Guidance for Industry S7A Safety 471 Pharmacology Studies for Human Pharmaceuticals and in FDA regulations, 21 CFR 472 part 58, now also apply to abuse potential studies in animals.
› Verified 9 days ago
Indravadan Ishwarbhai Patel, Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 66 Shaffer Rd, Bridgewater, NJ 08807 Phone: 908-392-6635 | |
Dr. Izzat H Shah, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1121 Route 22 Ste 201, Bridgewater, NJ 08807 Phone: 908-237-4110 | |
Lawrence Steven Perlow, M.D. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 1384 Plymouth Rd, Bridgewater, NJ 08807 Phone: 908-231-0329 | |
Dr. Ranjita Sengupta, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 465 Union Ave, Suite A, Bridgewater, NJ 08807 Phone: 908-722-6410 Fax: 908-722-4638 | |
Dr. Alpesh A Patel, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 245 Union Ave Ste 1a, Bridgewater, NJ 08807 Phone: 908-864-4027 Fax: 732-463-5510 | |
Dr. Glenn T Friedman, MD Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 225 Jackson Street, Bridgewater, NJ 08807 Phone: 908-526-8668 Fax: 908-231-6781 | |
Dr. Chandreshwar N Shahi, MD, FACC Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 245 Union Ave, Suite 1a, Bridgewater, NJ 08807 Phone: 908-864-4027 Fax: 908-864-4029 |